company background image
SANN logo

Santhera Pharmaceuticals Holding SWX:SANN Stock Report

Last Price

CHF9.25

Market Cap

CHF85.2m

7D

-2.8%

1Y

46.1%

Updated

14 Apr, 2024

Data

Company Financials +

Santhera Pharmaceuticals Holding AG

SWX:SANN Stock Report

Market Cap: CHF85.2m

SANN Stock Overview

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally.

SANN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health0/6
Dividends0/6

Santhera Pharmaceuticals Holding AG Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Santhera Pharmaceuticals Holding
Historical stock prices
Current Share PriceCHF9.25
52 Week HighCHF14.62
52 Week LowCHF6.04
Beta0.15
1 Month Change-3.14%
3 Month Change-8.23%
1 Year Change46.13%
3 Year Change-65.16%
5 Year Change-94.18%
Change since IPO-98.98%

Recent News & Updates

Recent updates

Shareholder Returns

SANNCH BiotechsCH Market
7D-2.8%18.0%-0.9%
1Y46.1%21.6%-2.9%

Return vs Industry: SANN exceeded the Swiss Biotechs industry which returned 21.6% over the past year.

Return vs Market: SANN exceeded the Swiss Market which returned -2.9% over the past year.

Price Volatility

Is SANN's price volatile compared to industry and market?
SANN volatility
SANN Average Weekly Movement5.1%
Biotechs Industry Average Movement7.6%
Market Average Movement3.5%
10% most volatile stocks in CH Market7.6%
10% least volatile stocks in CH Market1.9%

Stable Share Price: SANN has not had significant price volatility in the past 3 months.

Volatility Over Time: SANN's weekly volatility (5%) has been stable over the past year, but is still higher than 75% of Swiss stocks.

About the Company

FoundedEmployeesCEOWebsite
200446Dario Eklundwww.santhera.com

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company’s lead pipeline candidate includes Vamorolone, which is being developed for the treatments of Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises Lonodelestat to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies.

Santhera Pharmaceuticals Holding AG Fundamentals Summary

How do Santhera Pharmaceuticals Holding's earnings and revenue compare to its market cap?
SANN fundamental statistics
Market capCHF85.24m
Earnings (TTM)-CHF64.69m
Revenue (TTM)CHF5.16m

16.5x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SANN income statement (TTM)
RevenueCHF5.16m
Cost of RevenueCHF3.65m
Gross ProfitCHF1.52m
Other ExpensesCHF66.21m
Earnings-CHF64.69m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Apr 25, 2024

Earnings per share (EPS)-7.02
Gross Margin29.39%
Net Profit Margin-1,253.16%
Debt/Equity Ratio-94.9%

How did SANN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.